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Purpose: We aimed to reduce unnecessary prostatic biopsy in patients with high pros-
tate-specific antigen (PSA) by consideration of prostatic inflammation.
Materials and Methods: The investigation was conducted prospectively in 413 patients 
with a PSA level of 4 to 10 ng/ml from January 2004 to December 2009. All patients 
underwent the expressed prostatic secretion (EPS) or voided bladder urine 3 (VB3) test 
to be classified into two groups: positive group and negative group. Patients with a pos-
itive result on the EPS or VB3 test were treated with antibiotics for 2 months, and in 
cases in which the PSA level remained high, we performed prostate biopsy. In patients 
with a negative result on the VB3 test, we performed prostate biopsy directly. 
Results: Of the 413 study patients, 215 (52%) patients had positive findings on the EPS 
or VB3 test. After 8 weeks of antibiotics therapy, 53 of the 215 men avoided prostate 
biopsy because their PSA level was normalized. The other patients (162 of 215) still 
had elevated PSA levels of more than 4 ng/ml, including 7 patients in whom the biopsy 
revealed cancer. Patients with negative findings (198 of 413) underwent prostate 
biopsy. Of the 198 patients, 41 were diagnosed with prostate cancer. The total prostate 
cancer detection rate was 11.6% in our subjects, where as it was 20.7% in the patients 
with negative findings on the EPS or VB3 and 3.3% in the patients with positive find-
ings, respectively. 
Conclusions: In cases in which the PSA level is increasing, if we first exclude prostatitis 
and carry out a serial diagnostic procedure, it may help to reduce unnecessary prostatic 
biopsy.
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INTRODUCTION
The prostate-specific antigen (PSA) level has been an im-
portant diagnostic tool for detecting prostate cancer. It has 
been shown that an abnormal digital rectal examination 
(DRE) has markedly decreased and biochemical findings 
(elevated PSA) have increased over the past 20 years for 
the indication of prostate biopsy [1]. This means that evalu-
ation of prostate cancer is more and more based on the PSA 
level rather than on suspicious DRE. However, cancer de-
tection rates from biopsy in the presence of isolated PSA 
elevation and a normal DRE range between 30% and 40% 
[1]. Also, a high concentration of PSA can be found in benign 
disorders such as benign prostatic hyperplasia (BPH), uri-
nary tract infections, and bacterial prostatitis [2-5].
Histological prostatitis is a common entity in men with-
out clinical prostatitis. Although it has been reported that 
acute inflammation is necessary to cause PSA elevation, 
there is growing evidence that subclinical inflammation 
may also contribute to rises in PSA levels [6-9]. Further-
more, several investigators have shown that treatment of 
chronic prostatitis, when identified, can decrease PSA, Korean J Urol 2012;53:50-53
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FIG. 1. The process of prostate cancer 
detection considering PSA reduction 
after antibiotic treatment. PSA: pro-
state-specific antigen, EPS: expressed 
prostatic secretion, VB3: voided bla-
dder urine 3.
which suggests that the use of anti-microbial or anti-in-
flammatory drugs may reduce the number of men who need 
prostate biopsies [10,11]. 
There is no doubt that symptomatic prostatitis needs to 
be treated, but uncertainty exists about the appropriate 
management of asymptomatic patients with elevated PSA 
and normal DRE.
The aim of our study was to investigate the possibility 
of reducing the number of prostate biopsies in patients with 
a high PSA level showing a PSA decrease or normalization 
after antibiotic therapy. This approach could be useful in 
patients for whom it is necessary to postpone biopsy and 
in patients with previous negative biopsies who are willing 
to avoid biopsy until further PSA increase.
MATERIALS AND METHODS
This investigation was conducted prospectively among 413 
patients with a serum PSA level of over 4 ng/ml to under 
10 ng/ml from January 2004 to December 2009. Subjects 
were excluded if they had been treated by 5-alpha reduc-
tase inhibitor for more than 3 months or if they had a history 
of transurethral resection of the prostate. The PSA level 
was determined by using immunoenzymatic assay before 
DRE and transrectal ultrasonography (TRUS) to avoid 
false-positive results. To exclude prostatitis, all patients 
underwent the expressed prostatic secretion (EPS) or void-
ed bladder urine 3 (VB3) test to be classified into two 
groups. One group had positive findings on the EPS or VB3 
test and the other group had negative findings. The ex-
pressed prostatic secretions were collected on a glass slide. 
A cover slip was placed over the specimen and it was exam-
ined under high-power microscopy. A positive finding was 
defined as a white blood cell (WBC) count higher than 10 
in the prostate secretion after EPS or WBC higher than 10 
in VB3 urine after EPS. The patients with a positive result 
were treated with quinolone antibiotics for 2 months, and 
they were asked to return for repeat screening 2 months 
later. If the PSA level was still higher than 4 ng/ml after 
2 months, the patients underwent prostate biopsy. In the 
other cases, the patients avoided prostate biopsy. The pa-
tients with a negative EPS or VB3 test immediately under-
went prostate biopsy. The subjects underwent at least 10 
core biopsies with transrectal ultrasound-guided needle 
biopsy of the prostate. SPSS ver. 10.0 (SPSS Inc., Chicago, 
IL, USA) was used for the statistical analysis, and in-
dependent t-tests were used for analysis of the character-
istics of both groups. P-values of less than 0.05 were consid-
ered significant.
RESULTS
Of the 413 men studied, 215 (52%) patients had positive 
findings on the EPS or VB3 test. They received levofloxacin 
100 mg tid daily. Antibiotic treatments were administered 
for a total of 8 weeks in 215 patients. After 8 weeks of anti-
biotic therapy, serum PSA screening was repeated. Of the 
215 patients, 53 men avoided prostate biopsy because their 
serum PSA level had decreased to less than 4 ng/ml. The 
other patients (162 of 215) still had an elevated serum PSA 
level of more than 4 ng/ml, including 7 in whom the biopsy 
results revealed cancer. Patients with negative findings on 
the EPS or VB3 test (198 of 413) underwent prostate biopsy 
immediately (Fig. 1). Of these 198 patients, 41 were diag-
nosed with prostate cancer. The total prostate cancer de-
tection rate was 11.6% in our subjects, whereas it was 
20.7% in the patients with negative findings on the EPS or 
VB3 test and 3.3% in those with positive findings, 
respectively. 
The mean age was significantly different between the 
positive group (65.0) and the negative group (71.2). There 
were no significant differences in the mean initial serum 
PSA level or prostate volume between the groups (Table 1). Korean J Urol 2012;53:50-53
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TABLE 1. The characteristics of both patient groups according to 
the findings of the EPS or VB3 test
Negative group 
(n=198)
Positive group 
(n=215)
p-value
Age (yr)
Prostate volume
Serum PSA
Prostate cancer 
detection rate (%)
71.2±9.3
  42.5±23.0
  6.1±1.6
40 (20.7)
65.0±12.3
39.8±16.9
6.3±1.7
7 (3.3)
0.00
0.17
0.13
0.00
Values are presented as mean±standard deviation or number (%).
EPS, expressed prostatic secretion; VB3, voided bladder urine 3; 
PSA, prostate-specific antigen.
DISCUSSION
Since PSA was introduced in the 1980s as a variable for de-
tecting prostate cancer, the detection rate of prostate can-
cer has been increasing. It is true that an abnormal finding 
on a DRE or TRUS is an indication for prostate biopsy, but 
in the majority of cases, the PSA level is the most important 
factor in deciding whether we will proceed with prostate bi-
opsy [2]. 
However, it is reported that 30 to 40% of patients who test 
positive for prostate cancer in prostate biopsy proceeded 
when only the PSA was increased without any abnormality 
in the DRE or TRUS [1]. The specificity and sensitivity of 
PSA can result in high values in other positive diseases. 
The PSA may increase not only in BPH but also in urinary 
tract infection and bacterial prostatitis. The PSA can in-
crease in acute inflammation and silent infection [7-9,12]. 
Also, some researchers have reported that treatment with 
antibiotics and anti-inflammatory drugs for chronic pros-
tatitis can decrease the PSA and the necessity for prostate 
biopsy [7,10,11].
Nadler et al. [6] reported that the size and infection of the 
prostate can be a chief cause of PSA increase in the case of 
patients not diagnosed with prostate cancer. But Irani et 
al. [13] reported that even if there is an infiltration of in-
flammatory cells in the prostatic interstitium, it is not re-
lated to the PSA increase in the blood if the glandular epi-
thelial cell layer is not destroyed at the same time. Further-
more, it has been reported that the existence of infla-
mmatory cells of the interstitium or glandular tissue in the 
prostate biopsy has no statistical affiliation with the con-
centration of PSA in the blood [14,15]. Carver et al. [16] ar-
gued that National Institutes of Health (NIH) category IV 
asymptomatic prostatitis increases the PSA concentration 
in the blood, but its clinical significance is not that great-
because the mean differences with the normal group are 
2.3 ng/ml and 1.4 ng/ml, respectively. Pansadoro et al. [17] 
reported that there is an increase of the concentration of 
PSA in the blood in 71% of patients with acute prostatitis, 
15% of patients with chronic prostatitis, and 6% of patients 
with nonbacterial prostatitis, but there was no PSA in-
crease in patients who showed only symptoms of chronic 
prostatitis. Hasui et al. [18] found a relation of the PSA con-
centration in the blood with acute and chronic prostatitis 
accompanied by clinical symptoms identified histologi-
cally, but no relation in the case of deactivated prostatitis. 
Chang et al. [19] investigated 223 patients who tested neg-
ative in a prostate biopsy by classifying the infection level 
and reached the conclusion that the whole size of the pros-
tate is an important factor that contributes to the increase 
in the PSA concentration in the blood, but that there was 
no relation with the prostatitis level. 
The relationship of prostatitis and the PSA increase con-
tinues to stimulate dispute, and we suggest that the find-
ings mentioned above are not sufficient to explain the rea-
son for the PSA increase in the case of NIH category IV 
asymptomatic prostatitis. Nadler et al. [20] investigated 
421 patients with NIH category III chronic prostatitis and 
reported recently that the mean PSA concentration in the 
blood of the patients investigated was 1.97 ng/ml. Com-
pared with the level in the normal group of 1.72 ng/ml, this-
was a statistically significant increase, but it is still below 
the normal PSA range. Also, f-PSA, percent f-PSA, and the 
[-2] pPSA isoform show some increase with prostate cancer, 
but they are inappropriate to be used as biomarkers of pros-
tate cancer diagnosis because of their low specificity and 
sensitivity. 
Treatment with antibiotics in the case of chronic prosta-
titis and increased PSA results in a very significant PSA 
decrease [11]. But any special bacteria is found in 90% of 
cases of prostatitis with or without symptoms. This kind 
of investigation of the changes in PSA after treatment with 
antibiotics or anti-inflammatory drugs for nonbacterial 
prostatitis is uncommon. According to the report of Potts 
[7] among 122 patients with an average PSA increase of 
9.35 ng/ml, 51 (42%) patients were diagnosed with in-
fection by urinalysis after a massage of the prostate or pro-
static secretion (EPS). The patients were then treated with 
antibiotics for 4 weeks, and after 6 to 8 weeks they had a 
PSA examination. After the treatment, 22 of the 51 pa-
tients had a normal PSA concentration (average, 2.9 ng/ml) 
and they did not need a prostate biopsy. But there was a 
continuous increase of PSA in the remaining 29 patients, 
and among them, 9 patients were diagnosed with prostate 
cancer. In comparison with patients diagnosed with cancer 
in prostate biopsy after treatment with antibiotics, the PSA 
decrease in patients with benign biopsy results was sig-
nificantly greater (-1.3% vs. -21.3%). 
In the investigation carried out with 95 patients diag-
nosed with nonbacterial prostatitis and who showed an in-
crease of PSA, Bozeman et al. [10] proceeded with prostate 
biopsy in patients in whom the PSA value did not decrease 
after 4 weeks of treatment with antibiotics and anti-infla-
mmatory drugs. Among these, the PSA of 36.4% of patients 
decreased from 8.48 ng/ml to 5.39 ng/ml after treatment; 
in 44 patients (46.3%) the PSA decreased below 4 ng/ml, so 
they avoided prostate biopsy. In the remaining patients 
who underwent prostate biopsy, 13 patients (25.5%) were 
diagnosed with prostate cancer, 37 patients (72.5%) with Korean J Urol 2012;53:50-53
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chronic infection, and 1 patient (1.05%) with BPH. Among 
the patients diagnosed with prostate cancer, just 4.8% of 
patients had shown a PSA decrease from 8.32 ng/ml to 7.92 
ng/ml, which was not statistically significant. Therefore, 
the authors argued that chronic prostatitis is the chief 
cause of PSA increase and that treatment for prostatitis 
can decrease unnecessary prostate biopsy. 
But Hochreiter [21] argued that although the authors of 
two investigations considered that the patients were not 
diagnosed with prostate cancer because the PSA was de-
creased to less than 4 ng/ml, it was difficult to conclude that 
the patients in fact had no cancer. 
Our results should be interpreted with an under-
standing of our study limitations. It is not a certainty that 
PSA-normalized patients are cancer free after antibiotic 
therapy. Additional research is needed with pathologic 
confirmation for PSA-normalized patients. 
CONCLUSIONS
Chronic prostatitis may interfere with the interpretation 
of PSA levels for prostate cancer screening. There are no 
general guidelines that can be applied to all men with in-
creased PSA before prostate biopsy. In cases in which the 
PSA level is increasing, if we first exclude prostatitis and 
carry out a serial diagnostic procedure, it may help to re-
duce unnecessary prostate biopsy.
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